De­ci­phera re­vives hopes for Qin­lock with sub­group analy­sis, plots new PhI­II — but mar­ket re­ac­tion is mut­ed

More than a year ago, dis­ap­point­ing da­ta from a key Phase III seem­ing­ly shat­tered De­ci­phera’s hopes of mov­ing its ki­nase in­hibitor in­to ear­li­er lines of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.